ImmunityBio (IBRX) said Tuesday it completed submissions to the US Food and Drug Administration, including the supplemental biologics license application for ANKTIVA plus Bacillus Calmette-Guerin to treat BCG-unresponsive non-muscle invasive bladder cancer in papillary disease.

The company also submitted an expanded access protocol to the FDA to make ANKTIVA available for the treatment of lymphopenia, according to a statement.

ImmunityBio also reported preliminary net product revenue of about $16.5 million for Q1, up from $7.2 million in Q4.

Price: 2.91, Change: +0.02, Percent Change: +0.69